-
Breakthrough! CAR-T Upgrade: iPSC can mass-produce general-purpose CAR-T and cure a variety of cancers!
Time of Update: 2022-10-02
Fig. 7 EZH1 knockdown promotes in vitro T cell differentiation of iPSC (Source: [1])As an alternative to shRNA-mediated EZH1 gene knockout, the researchers constructed doxycycline-induced CRISPR interference (CRISPRi) into IPSC-derived CD34+ HE cells to transcriptionally inhibit the expression of EZH1.
-
【JCO Editorial】Is the treatment of diffuse large B-cell lymphoma getting smarter?
Time of Update: 2022-10-02
In early August, the Journal of Clinical Oncology reported on a researcher-initiated, single-armed, Phase II Smart Start study that explored a new combination regimen for the initial treatment of diffuse large B-cell lymphoma, namely rituximab, lenalidomide, and ibratinib (RLI).
-
Professor Ma Jun and Zhu Jun: The new anti-CD20 monoclonal antibody repatitumab has been heavily marketed, adding new strength to the treatment of lymphoma
Time of Update: 2022-10-01
With the continuous emergence of new drugs and the entry into the clinic, the overall survival status of lymphoma patients has been significantly improved, and the treatment mode of anti-CD20 monoclonal antibody combined with chemotherapy has become the first-line treatment standard for B-cell lymphomas such as diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL).
-
Prof. Lugui Qiu: Zebutinib was recommended as a priority in Class I of the 2023 V1 NCCN Guidelines
Time of Update: 2022-10-01
NCCN Guidelines Update and Interpretation Expert Introduction Qiu Lugui Professor Tianjin Umbilical Cord Blood Hematopoietic Stem Cell Bank, Director of the Umbilical Cord Blood Hematopoietic Stem Cel
-
The treatment of chronic myeloid leukemia breaks through the dilemma of drug resistance, and the Handbook of Return to Society helps patients return to formal life
Time of Update: 2022-10-01
" Professor Hu Yu of Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology emphasized: "I hope that through this conference, more people will have a deeper understanding of CML, be familiar with the current situation of CML diagnosis and treatment, and walk into the CML patient group to help patients re-create social value in the process of helping patients return to normal life.
-
The Danish Cosmos Anemia Management Satellite will be successfully held - iron isomaltose iron breaks through the limitations of iron supplementation, and it is safe at one time
Time of Update: 2022-10-01
Figure 4 Professor Zhang Xi made a wonderful summaryProfessor Zhang Xi, the chairman of the conference, summed up Professor Rong's wonderful sharing, saying that IDA is a common disease in the world, especially in developing countries, but everyone's understanding of the disease is seriously insufficient, and in the past IDA treatment, due to the limitation of low doses and high frequencies of intravenous iron treatment, iron deficiency cannot be corrected at one time.
-
2022 CSH Professor Wang Ying: A new breakthrough in CAR-T therapy, Herkirensai injection is expected to break the bottleneck of r/r B-ALL treatment
Time of Update: 2022-10-01
Figure 2 Immunotherapy mechanismFigure 3 The current approval status of CD19 CAR-T cell productsFigure 4 r/r ALL domestic and foreign guideline treatment recommendationsIn a clinical study (IIT) initiated by previous investigators of Hekylense, 30 adults (≥ 18 years old) patients with B-ALL and 30 children and adolescents (< 18 years old) B-ALL patients received Heckirensee cell therapy.
-
Blood friends new life, not to live up to Shaohua I Chu sail · Starting again, the tour of the frontier progress of hemophilia (Tianjin Station) was successfully held
Time of Update: 2022-10-01
Figure 6 Professor Zhou Zeping shares the latest database update of hemophiliaPoint 2: Emmy Saizumab helps improve the management confidence of hemophilia patientsIn terms of surgery, a number of clinical and real-world studies have shown that in patients receiving prophylactic treatment with Emmy Saizumab, minor surgery can be safely performed without additional coagulation factor supplementation; Major surgery is safe when used in combination with other hemostatic agents.
-
Lymphoma interview with Professor Ma Jun: Attacking the spear of "lymphatic", protecting the shield of "inertia", PI3K inhibitors bring clinical benefits to patients with indolent lymphoma
Time of Update: 2022-10-01
With the emergence of new drugs, the survival status of inert lymphoma patients has improved, but there are still some patients, especially POD24 patients, who are still facing the dilemma of relapse and refractory treatment, and the prognosis is poor, please combine your clinical experience to talk about the current progress of new drugs for relapsed refractory (R/R) indolent lymphoma?Professor Ma JunIndolent lymphoma is a common class of indolent NHL with high heterogeneity.
-
PK-guided individualized preventive treatment drives "3D" improvements in joint health
Time of Update: 2022-10-01
, evaluating the outcomes of PK-guided prophylaxis versus standard prophylaxis and developing discrete event simulation models to simulate the clinical outcomes of 10,000 adult patients with hemophilia A in China receiving 1 year of treatment, showed that 5:5that 5The proportion of patients with PK-guided individualized prophylaxis maintained at 1-5 IU/dL was higher (62.
-
Cancer Discov: CAR-T cell therapy that overexpresses BCL-2, the efficacy of "anti-cancer weapon" is further improved!
Time of Update: 2022-09-30
Since the first CAR-T cell therapy was launched in 2017, the era of cell therapy has officially begun, and it has achieved good clinical results in a variety of tumor treatments, and B-cell lymphoma i
-
【Nat Med】A real-world analysis of axi-cel versus tisa-cel treatment of 809 cases of R/R DLBCL
Time of Update: 2022-09-30
CD19 CAR T cell therapy has shown impressive efficacy and controlled toxicity in the treatment of a variety of histological subtypes of lymphoma, such as mantle-cell lymphoma, follicular lymphoma, and
-
J Fungi (Basel) . : Invasive mycoses in patients with bone marrow malignancies: a retrospective cohort study of diagnostic-driven care pathways, preserving mold activity for prevention
Time of Update: 2022-09-30
One study reported on the experience of a diagnostic-driven approach to care (DCP) in managing IFD in these patients, using only culture-guided mold-inactive prophylaxis.
One study reported on the experience of a diagnostic-driven approach to care (DCP) in managing IFD in these patients, using only culture-guided mold-inactive prophylaxis.
-
【Am J Hematol Review】Treatment of relapsed/refractory chronic lymphocytic leukemia
Time of Update: 2022-09-30
Venecra is treated with relapsed/refractory CLL Vinectra is an orally bioavailable, selective BCL2 inhibitor that exhibits excellent activity in recurrent CLLs. In the Phase 1 study of continued monotherapy, the overall response rate for patients receiving the recommended dose was 82%, and the median PFS was 25 months, with a shorter duration of remission (16 months) in del(17p) patients.
-
Chinese exploration of BTKi, rituximab, and lenalidomide in the treatment of DLBCL
Time of Update: 2022-09-30
e. , rituximab (d1,375 mg/m2 intravenously) + lenalidomide (25 mg orallyd2-15) + BTK inhibitor (ibratinib 560 mg orally once daily, or zebubutinib 160 mg twice daily, or obupinib 150 mg once daily) for a 21-day cycle for 6-8 cycles 。 The SMART-START group included unfit DLBCL patients who could not tolerate intensive therapy, who received the SMART regimen for the first 2-3 cycles and then added chemotherapy.
-
AJH: first-line treatment of CML in the chronic phase, dasatinib 50 mg is not inferior to 100 mg
Time of Update: 2022-09-30
Response rateThe overall median follow-up time after matching the propensity score was 60 months: 48 months for the low-dose and 131-month cohorts for the standard dose, respectively.
-
Ann Transl Med: analysis of m6A-related features associated with the tumor immune microenvironment and prediction of survival in acute myeloid leukemia
Time of Update: 2022-09-30
The research team built a prognostic model using m6A-related features associated with TIME to predict the survival of AML patients.
The research team built a prognostic model using m6A-related features associated with TIME to predict the survival of AML patients.
-
Thinking triggered by the "past and present lives" of a patient with a recurrent disability
Time of Update: 2022-09-30
Bone marrow smear results: there is a decrease in nucleocyte hyperplasia in this area, an increase in the proportion of lymphocytes, and some bone marrow particles are empty, please combine clinical and other related examinations.
-
【September 26 (Monday) 19:00 Starlight】The hormone session is about to start!
Time of Update: 2022-09-30
In recent years, the research and application of CAR-T cell therapy has been in full swing around the world, and has shown excellent therapeutic effects in a variety of malignant blood diseases, making the clinical cure of malignant blood diseases possible, and rekindling the hope for countless patients and families.
-
BJH: allogeneic hematopoietic cell transplantation in patients with relapsed/refractory anaplastic large-cell lymphoma
Time of Update: 2022-09-30
Non-recurrence mortality (NRM), disease modeled recurrence/progression (REL), progression-free survival (PFS), and overall survival (OS) using the Cox proportional risk model.
Non-recurrence mortality (NRM), disease modeled recurrence/progression (REL), progression-free survival (PFS), and overall survival (OS) using the Cox proportional risk model.
